Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.45 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 17/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15969820 | 0.85 | CNR2 (0.47) | CNR2 | |
| SCHEMBL15776274 | 0.84 | CNR2 (0.60) | KMOCNR2 | |
| SCHEMBL15351261 | 0.82 | KMO (0.48) | KMOCNR2 | |
| SCHEMBL21045798 | 0.82 | TRPC6 (0.55) | KMOCNR2 | |
| SCHEMBL88281 | 0.82 | TRPC6 (0.49) | KMOCNR2 | |
| SCHEMBL15777115 | 0.81 | CNR2 (0.56) | KMOCNR2 | |
| SCHEMBL15776512 | 0.79 | CNR2 (0.64) | KMOCNR2 | |
| SCHEMBL15776294 | 0.78 | CNR2 (0.58) | KMOCNR2 | |
| SCHEMBL30680327 | 0.78 | CNR2 (0.66) | KMOCNR2 | |
| SCHEMBL411450 | 0.78 | CNR2 (0.66) | KMOCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | KMO 2615/4885KDM4E 1635/4885ASPH 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.